AstraZeneca’s medicine for non-small lung cancer gets EU nod
HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.
The national public health agency of the US has reported a fourth person who was infected in the country with the highly pathogenic.
The European Medicines Agency has approved Sanofi S.A.’s Dupixent (dupilumab) therapy as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary.
Scotland's researchers and doctors have performed a non-invasive operation on a patient with Parkinson’s disease using the country’s first ultrasound thalamotomy that allowed.
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.
The European Medicines Agency has allowed marketing authorisation for the Covid-19 variant vaccine made by Pfizer and BioNTech SE for children aged six.
HQ Team June 27, 2024: A new study has found that the removal of both ovaries can have long-term health consequences The US.
HQ Team June 27, 2024:The ongoing debate about the perceived benefits or non-benefits of vitamin supplements has another study that emphasises their nil.
In a bid to include an under-represented population, the US drug regulator has advised healthcare firms to improve racial, ethnic and other diversity.